SiBone (NASDAQ:SIBN) Director Sells $378,200.00 in Stock

SiBone (NASDAQ:SIBN) Director Jeffrey Dunn sold 20,000 shares of SiBone stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $18.91, for a total transaction of $378,200.00. Following the completion of the transaction, the director owned 16,057 shares in the company, valued at approximately $303,637.87. This represents a 55.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

SiBone Price Performance

Shares of NASDAQ:SIBN opened at $18.50 on Friday. SiBone has a one year low of $11.48 and a one year high of $21.89. The stock has a market capitalization of $820.48 million, a price-to-earnings ratio of -54.41 and a beta of 0.70. The company has a 50-day simple moving average of $18.12 and a 200-day simple moving average of $15.57. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.55 and a current ratio of 9.15.

SiBone (NASDAQ:SIBN) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.06. The firm had revenue of $56.01 million for the quarter, compared to analyst estimates of $55.34 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. On average, analysts predict that SiBone will post -0.4 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. UBS Group upped their price target on SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. TD Cowen lifted their price objective on shares of SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Truist Financial reissued a “buy” rating and issued a $23.00 price objective (up from $21.00) on shares of SiBone in a research note on Tuesday, August 4th. Finally, Weiss Ratings upgraded shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, SiBone currently has an average rating of “Moderate Buy” and a consensus price target of $24.17.

Institutional Trading of SiBone

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada boosted its holdings in SiBone by 98.5% during the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock worth $29,000 after buying an additional 736 shares in the last quarter. Versant Capital Management Inc increased its holdings in SiBone by 102.9% in the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after buying an additional 887 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of SiBone by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock valued at $343,000 after acquiring an additional 1,053 shares during the period. Larson Financial Group LLC lifted its position in shares of SiBone by 42.3% during the 4th quarter. Larson Financial Group LLC now owns 3,569 shares of the company’s stock valued at $70,000 after acquiring an additional 1,061 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of SiBone by 4.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,159 shares of the company’s stock worth $733,000 after acquiring an additional 1,459 shares in the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.